About
Dr. Melya Hughes Crameri joined Ventac Partners in February 2015. She brings over 20 years of experience in the life science industry both in the United States and Europe, working primarily with early stage companies and academic innovation. Melya has served as a consultant to multiple early stage companies in the US, UK, Switzerland and Italy. Prior to Joining Ventac Partners, she was Founder & CEO of Caltherix Inc. a peptide-based technology spin-out of Amunix Inc. She served as VP Alliances & Intellectual Property of Evolva SA, a synthetic biology company, from Series A to its exit on the SIX Swiss Exchange (SIX:EVE), and was Founder & CEO of Genetic Chemistry Inc. (Evolva’s US subsidiary), securing multi-million dollar discovery contracts and supporting $50M in venture funding. Previously, she served as Head of Licensing and Patents, Novartis Research Foundation (FMI) developing and executing on their first patent and business strategy. Her executive experience has crossed multipl
Position in the VCSift Database
- • 14 investors at Ventac Partners are tracked.
- • 2,531 investors hold the Partner role in VCSift. Melya Hughes Crameri is one of them.
- • 8,972 investors are based in London, England, United Kingdom.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- London, UK
Contact Information
Find more investors like Melya Hughes
Search Investors